Among patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and who received dual antiplatelet therapy (DAPT) of aspirin and clopidogrel, high platelet reactivity was associated with all-cause mortality and other adverse events at both 1 and 5 years compared to low platelet reactivity, new study results show.